Log in for full access to this activity, if you are registered.

Registration Options

Activity Dates: 04/18/2010 - 04/18/2013

This course is closed. Please look for other available products in CPNP University.

Target Audience

If you are a pharmacist, nurse practitioner or other healthcare professional involved in the comprehensive medication management of psychiatric and/or neurological patients, we invite you to participate in this online course.

Session Summary

Potential additions to health system formularies are reviewed for safety, efficacy, therapeutic need, and cost.  Formularies in mental health have separate issues that must be considered.  Clinical decision-making without knowledge from well-designed, controlled, randomized trials with adequate sample size, can incorrectly estimate the efficacy and safety risks associated with specific drug therapy.  The practice of evidence-based medicine (EBM) involves integrating clinical expertise with the best available evidence from systematic research.

The application of EBM principles is very important in making formulary management decisions.  However, in some instances this proves difficult as data is lacking.  Drugs that offer significant clinical advantages over current alternatives at a lesser cost are typically added to all formularies with minimal effort.  However," me too” agents may not differ much from other available medications and are more closely scrutinized.  Pure enantiomer products which offer subtle differences from the original compound pose a special quandary to those involved in formulary decision-making as often, the clinical differences may not be detectable especially if there are no head-to-head trials available.

Further complicating this picture is the role of marketing with these medications.  ”Me too” drugs are frequently released well before the patent expires on the original medication, when the costs should decrease substantially.  Formulary managers should take all information into account and use the evidence available when deciding where to place these medications in their health care system.  A systematic EBM process can assist with this challenge.  This session will discuss the activity and issues of formulary management and provide a 5-step EBM process that ensures clinical decisions are made based on the available evidence.

Course Requirements

You will proceed through the following steps to satisfactorily complete this course:

  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date. (login first)
  • Complete the evaluation at the end of the activity. (login first)
  • Receive a passing grade (60%).
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor. (login first)

This course is provided online at cpnp.org and consists of the speaker audio and slides. A PDF file of the slides is also provided and access is available to participants indefinitely although ACPE credit is available only through the course expiration date.

Participants in this course must complete an examination and achieve a score of 60% or greater. Successful completion of the course also requires the completion of a course evaluation. ACPE statements of credit can be retrieved by participants online at cpnp.org immediately upon successful completion of the course.

Faculty Information and Disclosures

Patrick Bryant PharmD, FSCIP
Cynthia A. Mascarenas, PharmD, MS, BCPP

View biographical information and disclosures

Learning Objectives

  1. Identify steps for formulary addition of medications in different practice settings.
  2. Compare common reasons for medications to be added or deleted from medication formularies.
  3. Explain concerns associated with the decision making process of approving a medication onto a formulary when the medication is a specific isomer of or has a different delivery mechanism from an existing product.
  4. Describe the basic principles in preparing and completing an evidence-based medicine review.
  5. Explain the critical analysis 5-Step EBM Process and provide an example of its application in the formulary review process.
  6. Discuss options for formulary decision-making when the desired quality or level of data does not exist.

Continuing Education Credit and Disclosures

Activity Dates: 04/18/2010 - 04/18/2013
ACPE Contact Hours: 2.0
ACPE Number: 0284-0000-10-003-H01-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This self-study course provides 2.0 contact hours (0.20 CEUs) of knowledge-based continuing education credit from CPNP approved programming. The ACPE universal program number assigned to this course is 0284-0000-10-003-L01-P (2.0 contact hours).

ACPE approved contact hours are accepted for ANCC Certification Renewal (see pages 5 and 6): At least 50% (37.5 hours) of your 75 continuing education hours must be formally approved continuing education hours. Formally approved continuing education hours meet one or more of the criteria listed below:

  1. Continuing nursing education (CNE) approved for nursing contact hours by an accredited provider or approver of nursing continuing education
  2. Continuing medical education (CME) approved for CME hours
  3. Sponsored by organizations, agencies, or educational institutions accredited or approved by the American Nurses Credentialing Center (ANCC) or the Accreditation Council for Continuing Medical Education (ACCME) or the Accreditation Council for Pharmacy Education (ACPE) or the Commission on Dietetic Registration

Grant Support

This programming was supported in part by grants from Janssen, Ortho-McNeil Janssen Scientific Affairs, LLC, supported by an educational grant from Janssen, Division of Ortho-McNeil Janssen Pharmaceuticals, Inc. administered by Ortho-McNeil Janssen Scientific Affairs, LLC. and Lilly USA, LLC.

Annual Meeting Grant Supporter

This activity is supported by an educational grant from Lilly USA, LLC. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Recertification Education Grant Provider

Supported by an educational grant from Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., administered by Ortho-McNeil Janssen Scientific Affairs, LLC

This activity is supported by an educational grant from Lilly USA, LLC. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.